News about Global Pharma

Glenmark Launches TEVIMBRA in India for Lung and Esophageal Cancer Treatment

Glenmark Launches TEVIMBRA in India for Lung and Esophageal Cancer Treatment

Glenmark Pharmaceuticals has launched TEVIMBRA (tislelizumab) in India, marking its entry into immuno-oncology with a globally approved PD-1 inhibitor for advanced lung and esophageal cancers.

Global Pharma | 24/06/2025 | By Manvi |  263

PharmaJet, Immuno Cure Partner for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine

PharmaJet, Immuno Cure Partner for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine

PharmaJet has partnered with Immuno Cure to provide its needle-free Tropis ID system for delivering ICVAX, a novel therapeutic HIV-1 DNA vaccine, in a human clinical trial—aiming to enhance vaccine performance and patient experience while advancing toward a functional HIV cure.

Global Pharma | 23/06/2025 | By Manvi |  153

IONETIX and AlfaRim Announce Strategic Collaboration on Cyclotron-Produced Actinium-225

IONETIX and AlfaRim Announce Strategic Collaboration on Cyclotron-Produced Actinium-225

IONETIX and AlfaRim announced a strategic collaboration to commercialize cyclotron-produced actinium-225, a key isotope enabling next-generation targeted alpha therapies (TATs).

Global Pharma | 23/06/2025 | By Manvi |  293

Ratio Therapeutics and TerraPower Isotopes Partner on Actinium-225 Supply for Cancer Drug Development

Ratio Therapeutics and TerraPower Isotopes Partner on Actinium-225 Supply for Cancer Drug Development

Under the agreement, TerraPower Isotopes would supply Ratio with quantities of non-cGMP Ac-225 for use to incorporate into or use in the development of Ratio's radiopharmaceuticals.

Global Pharma | 21/06/2025 | By Manvi |  202

Catalyst MedTech Named Exclusive US Distributor of CareMiBrain

Catalyst MedTech Named Exclusive US Distributor of CareMiBrain

Catalyst MedTech has announced it will serve as the exclusive US distributor of CareMiBrain™, an ultra-high resolution dedicated brain PET system developed by MindView / OncoVision.

Global Pharma | 21/06/2025 | By Manvi |  125

Palvella Therapeutics Secures US Patent for QTORIN Rapamycin

Palvella Therapeutics Secures US Patent for QTORIN Rapamycin

Palvella Therapeutics has secured its sixth US patent for QTORIN 3.9 percent rapamycin gel, strengthening intellectual property protection around its lead candidate for rare genetic skin diseases with no approved FDA therapies.

Global Pharma | 21/06/2025 | By Manvi |  193

FDA Clears Happy Ring as Class II Device for At-Home Sleep Disorder Diagnosis

FDA Clears Happy Ring as Class II Device for At-Home Sleep Disorder Diagnosis

Through the company's Happy Sleep platform, individuals order a sleep test online, wear the ring overnight, and review the results with a board-certified sleep physician – all in the comfort of their own home.

Global Pharma | 20/06/2025 | By Manvi |  495

Advanced Wellness Center Debuts Cutting-Edge Muscle Activation for Fat Loss and Recovery

Advanced Wellness Center Debuts Cutting-Edge Muscle Activation for Fat Loss and Recovery

Advanced Wellness Center is one of the first health centers in the area to offer leading-edge, noninvasive technology using muscle activation to build muscle, burn fat, help with muscle injury and recovery, and strengthen the pelvic floor.

Global Pharma | 20/06/2025 | By Manvi |  175

Pierre Fabre Laboratories Acquires Worldwide Rights for PFL-721 and PFL-241 from Antares Therapeutics

Pierre Fabre Laboratories Acquires Worldwide Rights for PFL-721 and PFL-241 from Antares Therapeutics

Pierre Fabre Laboratories has acquired global rights to two next-generation EGFR inhibitors – PFL-721 and PFL-241 – from Antares Therapeutics, strengthening its oncology pipeline with precision therapies targeting non-small cell lung cancer.

Global Pharma | 20/06/2025 | By Manvi |  250

Circle Pharma Secures US FDA Orphan Drug Designation for CID-078 for Treatment of Small Cell Lung Cancer

Circle Pharma Secures US FDA Orphan Drug Designation for CID-078 for Treatment of Small Cell Lung Cancer

Circle Pharma, a clinical-stage biotech firm developing macrocycle therapeutics for hard-to-treat cancers, has received Orphan Drug Designation from the US FDA for its investigational drug CID-078 targeting small cell lung cancer.

Global Pharma | 20/06/2025 | By Manvi |  157

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members